rs61816761 — FLG R501X

FLG R501X — The Broken Skin Barrier

Your skin is not just packaging — it is an active immune organ, and at its center sits filaggrin. The FLG gene encodes profilaggrin¹¹ profilaggrin
a massive precursor protein cleaved into 10–12 filaggrin monomers during terminal differentiation of the epidermis, the protein responsible for aggregating keratin filaments into the dense, waterproof matrix of the outermost skin layer (stratum corneum). Filaggrin is then broken down into natural moisturizing factor (NMF)²² natural moisturizing factor (NMF)
a mixture of amino acids, urocanic acid, pyrrolidone carboxylic acid, urea, and ions that maintains stratum corneum hydration and regulates skin pH. The R501X variant (c.1501C>T) introduces a premature stop codon at position 501 of the protein, eliminating filaggrin production entirely from that allele — making it the most consequential single-nucleotide skin barrier variant known³³ the most consequential single-nucleotide skin barrier variant known
FLG loss-of-function mutations represent the strongest identified genetic risk factor for atopic dermatitis and ichthyosis vulgaris.

The Mechanism

Filaggrin haploinsufficiency (one non-functional copy) substantially reduces filaggrin protein levels, directly impairing barrier assembly and NMF production. The downstream consequences cascade across multiple systems. Without adequate NMF, transepidermal water loss (TEWL) increases, stratum corneum hydration falls, and skin pH rises above the optimal acidic range (pH 4.5–5.5). An alkaline skin surface dysregulates serine protease activity, accelerates corneocyte shedding, and impairs the acidic mantle's natural suppression of Staphylococcus aureus colonization. Structural gaps between corneocytes allow environmental allergens — house dust mite, pollen, food proteins⁴⁴ house dust mite, pollen, food proteins
Percutaneous sensitization through the defective barrier is the primary route for IgE sensitization and food allergy in FLG-null carriers — to penetrate into the viable epidermis, triggering IgE sensitization and Th2-skewed immune responses. This is the molecular foundation of the "atopic march."

The Evidence

R501X was identified in 2006 as the primary cause of ichthyosis vulgaris⁵⁵ ichthyosis vulgaris
a common inherited skin condition causing fish-scale dryness and rough skin and simultaneously as a major predisposing factor for atopic dermatitis⁶⁶ major predisposing factor for atopic dermatitis. The inheritance pattern is semidominant: heterozygotes show mild or no ichthyosis but substantially elevated eczema risk, while homozygotes and compound heterozygotes (carrying R501X on one chromosome and another FLG null allele such as 2282del4 on the other) exhibit overt ichthyosis and severe eczema.

A meta-analysis of 11 studies⁷⁷ meta-analysis of 11 studies
Baurecht et al. 2007: meta-analysis confirming OR 4.09 for FLG null mutations and atopic eczema from case-control studies established the odds ratio for atopic eczema as 4.09 (95% CI 2.64–6.33) from case-control data and 2.06 (95% CI 1.76–2.42) from family studies. A subsequent meta-analysis of 24 studies⁸⁸ meta-analysis of 24 studies
Rodríguez et al. 2009: FLG mutations are robust risk factors for eczema (OR 3.12) and eczema-associated asthma (OR 3.29) confirmed eczema risk (OR 3.12; 95% CI 2.57–3.79) and found that asthma risk is primarily driven by the eczema-asthma compound phenotype (OR 3.29; 95% CI 2.84–3.82), supporting percutaneous sensitization as the dominant mechanism.

FLG carriers face an elevated risk of eczema herpeticum⁹⁹ eczema herpeticum
a severe, potentially life-threatening herpes simplex virus infection of eczematous skin — the frequency of R501X was three times higher in eczema herpeticum patients than in eczema patients without this complication (25% vs 9%, OR 3.4). The variant also promotes Staphylococcus aureus colonization through impaired antimicrobial peptide function and disrupted skin pH.

A randomized controlled trial¹⁰¹⁰ randomized controlled trial
Simpson et al. 2014 JACI: daily emollient from birth reduced cumulative AD incidence by 50% in high-risk infants over 6 months demonstrated that daily emollient application from birth reduced cumulative atopic dermatitis incidence by approximately 50% in high-risk infants — providing direct evidence that barrier augmentation can interrupt the atopic march at its earliest stage.

Practical Actions

The central actionable insight from R501X carrier status is that the skin barrier needs external support that a non-carrier's skin provides internally. For carriers with existing eczema, ceramide-dominant emollients containing the physiologic 3:1:1 ratio of ceramides to cholesterol to free fatty acids most closely replicate what a functional stratum corneum would produce. Urea-containing emollients (10–25% urea) are specifically beneficial because urea is both an NMF component and promotes residual FLG expression — addressing the deficit from two angles. Fragrance, preservatives (especially methylisothiazolinone), and sodium lauryl sulfate in skincare products all exacerbate barrier disruption disproportionately in FLG carriers and should be avoided.

Heterozygous carriers who are not currently eczematous should consider proactive moisturizing during skin stress periods (low humidity, cold weather, frequent handwashing, swimming) to prevent barrier compromise that could initiate sensitization.

For parents carrying R501X: early, consistent emollient use in newborns at family risk is supported by RCT evidence for eczema prevention. Early oral introduction of allergenic foods (peanut, egg) — consistent with current LEAP-trial-informed guidelines — is particularly important in FLG carrier families because percutaneous sensitization through the defective barrier precedes oral tolerance and can establish food allergy before intentional food introduction.

Interactions

The two most common European FLG loss-of-function variants, R501X (rs61816761) and 2282del4 (rs558269137), interact as compound heterozygotes. An individual carrying one copy of each on separate chromosomes has no functional FLG gene — equivalent to homozygosity — and shows the most severe phenotype: overt ichthyosis vulgaris, high-penetrance eczema, and substantially elevated asthma risk. This compound heterozygous state is the most clinically significant FLG interaction.

Interaction between FLG null carrier status and early food sensitization creates a synergistic effect on asthma risk that exceeds the sum of independent effects. This means that preventing IgE food sensitization (through early allergen introduction) in FLG-carrier infants is particularly high-impact.

If both R501X (rs61816761) and 2282del4 (rs558269137) are carried — one on each chromosome — the individual is compound heterozygous and effectively FLG-null, with complete filaggrin absence. This is the most severe FLG genotype and warrants intensive daily ceramide-dominant emollient therapy (twice daily minimum), dermatology referral for personalized management, proactive monitoring for eczema herpeticum, early allergen introduction in offspring, and strict avoidance of all barrier-disrupting personal care ingredients (fragrance, methylisothiazolinone, sodium lauryl sulfate, propylene glycol).